- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Alain Mina, MD
Biography
Alain Mina, MD, specializes in medical oncology and hematology, with a focus on leukemia as well as stem cell transplants and cell therapy. Dr. Mina is dedicated to diagnosing and treating blood-related cancers, offering patients a combination of chemotherapy and advanced cellular therapies to manage their conditions effectively.
As an assistant professor of medicine at Yale School of Medicine, Dr. Mina conducts research of myeloid malignancies, such as myelodysplastic syndromes and acute myeloid leukemia. He focuses on discovering new therapies that can be tested in clinical trials.
Dr. Mina received his medical degree from the American University of Beirut in Lebanon, followed by a residency at University of Kansas Medical Center. He completed fellowships in hematology and oncology at McGaw Medical Center of Northwestern University, and in blood and marrow transplantation and cellular therapy at Stanford University Medical Center.
Titles
- Assistant Professor of Medicine (Medical Oncology & Hematology)
Education & Training
- MDAmerican University of Beirut
Languages Spoken
- العربية (Arabic)
- English
- Français (French)
Additional Information
- Mina A, Xu Y, Kapustyan T, Dhalla M, Chen C, Kamalakar R, Lin C, Ma E, Montez M, Wu Z, Yee T, Sun H, Rava A, Kim S, Huntington S, Zeidan A. Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy. Leukemia & Lymphoma 2026, ahead-of-print: 1-9. PMID: 42437458, DOI: 10.1080/10428194.2026.2691911.
- Alhajahjeh A, Beke K, Grimshaw A, Aguirre L, Mina A, Podoltsev N, Mendez L, Stahl M, Zeidan A, Bewersdorf J. Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis. Leukemia & Lymphoma 2026, 67: 1662-1674. PMID: 42251692, DOI: 10.1080/10428194.2026.2682397.
- Zhao A, Pirsl F, Parkin J, Mina A, Hishmeh R, Holtzman N, Schulz E, Pavletic S, Jurdi N. Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-versus-Host Disease. Transplantation And Cellular Therapy 2026, s2666-6367(26)00427-6. PMID: 42208939, PMCID: PMC13403212, DOI: 10.1016/j.jtct.2026.05.034.
- Mina A, Calvo K, McKinnon K, Raman A, Wang W, Cunningham L, Liu Y, Alexander R, Larson D, Pavletic S, McGraw K. Targeting the IL-8 axis in high-risk myelodysplastic syndromes: a clinical experience with antibody blockade combined with decitabine/cedazuridine. Leukemia & Lymphoma 2026, 67: 1740-1748. PMID: 42047494, DOI: 10.1080/10428194.2026.2661078.
- Bewersdorf J, Wang R, Mendez L, Mina A, Aguirre L, Stahl M, Zeidan A, Ma X, Podoltsev N. Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States. Cancer 2026, 132: e70415. PMID: 42033416, DOI: 10.1002/cncr.70415.
- Bewersdorf J, Mina A, Stahl M, Zeidan A. A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions. Nature Reviews Clinical Oncology 2026, 23: 481-500. PMID: 41981151, DOI: 10.1038/s41571-026-01141-2.
- Mina A, Zeidan A. Targeting metabolism in acute myeloid leukemia: the next therapeutic frontier? Chinese Clinical Oncology 2026, 15: 24-24. PMID: 42145008, DOI: 10.21037/cco-2025-1-191.
- Mina A, Zeidan A. Pharmacologic progress in higher-risk MDS: an uphill battle. Expert Opinion On Pharmacotherapy 2026, 27: 193-210. PMID: 41804943, DOI: 10.1080/14656566.2026.2644384.
- Beauchamp E, Jain A, Clutter M, Nahotko D, Fajardo E, Vagadia P, Dunne S, Mina A, Fischietti M, Oku C, Blyth G, Mishra R, Karras E, Radecki S, Lantz C, Addepalli S, Modi M, Zou L, Cho B, Goo Y, Rossoff J, Fish E, Saleiro D, Schiltz G, Platanias L. Development of a SIN1 targeting inhibitor as a novel therapeutic approach for the treatment of malignancies. Molecular Cancer Therapeutics 2025, 25: 1111-1129. PMID: 41423418, PMCID: PMC12904549, DOI: 10.1158/1535-7163.mct-25-0298.
- Alhajahjeh A, Woite N, Rolles B, Stempel J, Mina A, Mendez L, Kewan T, Podoltsev N, Stahl M, Grimshaw A, Zeidan A, Bewersdorf J. Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis. Blood Advances 2025, 9: 6511-6523. PMID: 40966428, PMCID: PMC12767819, DOI: 10.1182/bloodadvances.2025017611.
- Mina A. Facing Death. JCO Oncology Practice 2025, 22: 732-734. PMID: 41380109, DOI: 10.1200/op-25-00864.
- Schulz E, Curtis L, Holtzman N, Steinberg S, Wloka K, Ostojic A, Mina A, El Jurdi N, Pirsl F, Carpenter A, Golagha M, Sirajuddin A, Heller T, Shaffer B, Hakim F, Rubin J, Gress R, Pavletic S. Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT. Blood 2025, 146: 944-950. PMID: 40331908, PMCID: PMC12783510, DOI: 10.1182/blood.2024028303.
- Jurdi N, Waldman M, Schulz E, Mina A, Li G, Carpenter A, Theis J, Sethi S, Caza T, Seshan S, Pavletic S. Diagnostic approaches for haematopoietic cell transplantation‐associated membranous nephropathy: Novel underutilized tools. British Journal Of Haematology 2025, 207: 1138-1142. PMID: 40589069, PMCID: PMC12302402, DOI: 10.1111/bjh.20232.
- Hoff F, Schulz E, Pavletic S, Mina A. Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance. Blood Reviews 2025, 74: 101319. PMID: 40582916, PMCID: PMC12308840, DOI: 10.1016/j.blre.2025.101319.
- Abdelhakim H, Hebishy A, Shune L, McGuirk J, Baran A, Allin D, Mina A, Aljitawi O. Impact of hyperbaric oxygen on post-UCB transplant blood transfusion and growth factor support. Transfusion And Apheresis Science 2025, 64: 104176. PMID: 40543291, DOI: 10.1016/j.transci.2025.104176.
- Mina A, Madanat Y, Abaza Y, Zeidan A. Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights. Blood Reviews 2025, 73: 101301. PMID: 40450506, DOI: 10.1016/j.blre.2025.101301.
- Jurdi N, Holtzman N, Hishmeh R, Mina A, Schulz E, Stokes A, Li G, Schmidt K, Figg W, Micheletti N, Mays J, Cowen E, Pavletic S, Pusic I. A phase 2 study of single agent ibrutinib for first‐line treatment of chronic graft‐versus‐host disease: A new paradigm and lessons learned. British Journal Of Haematology 2025, 206: 1822-1827. PMID: 40322855, PMCID: PMC12302506, DOI: 10.1111/bjh.20069.
- Mina A, Komrokji R. How I treat higher-risk MDS. Blood 2025, 145: 2002-2011. PMID: 39808802, PMCID: PMC12782972, DOI: 10.1182/blood.2024025271.
- Schulz E, Pirsl F, McGraw K, Nousome D, Liu Y, Goklemez S, Mina A, Holtzman N, El Jurdi N, Pavletic S. Prevalence of clonal hematopoiesis of indeterminate potential in patients with severe chronic graft-versus-host disease. Bone Marrow Transplantation 2025, 60: 725-728. PMID: 40057632, DOI: 10.1038/s41409-025-02537-x.
- Mina A, McGraw K, Cunningham L, Kim N, Jen E, Calvo K, Ehrlich L, Aplan P, Garcia-Manero G, Foran J, Garcia J, Zeidan A, DeZern A, Komrokji R, Sekeres M, Scott B, Buckstein R, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic S, Norsworthy K. Advancing drug development in myelodysplastic syndromes. Blood Advances 2025, 9: 1095-1104. PMID: 39786387, PMCID: PMC11914162, DOI: 10.1182/bloodadvances.2024014865.
- Mina A. Targeted therapy in acute T-cell leukemia/lymphoma: are we close? Leukemia & Lymphoma 2024, 65: 2071-2073. PMID: 39618171, DOI: 10.1080/10428194.2024.2432575.
- Mendoza T, King A, Vera E, Mina A, McGraw K, Pavletic S, Armstrong T. Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes. Seminars In Hematology 2024, 61: 457-464. PMID: 39542751, DOI: 10.1053/j.seminhematol.2024.10.010.
- Schulz E, Pavletic S, Mina A. Allogeneic hematopoietic cell transplantation in elderly patients with myelodysplastic syndromes: Considerations and challenges. Seminars In Hematology 2024, 61: 420-430. PMID: 39523201, PMCID: PMC11646184, DOI: 10.1053/j.seminhematol.2024.10.004.
- Gavrilova T, Schulz E, Mina A. Breaking Boundaries: Immunotherapy for Myeloid Malignancies. Cancers 2024, 16: 2780. PMID: 39199554, PMCID: PMC11352449, DOI: 10.3390/cancers16162780.
- Czech M, Schulz E, Mina A, Gea-Banacloche J. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes. Seminars In Hematology 2024, 61: 348-357. PMID: 39198132, PMCID: PMC11646186, DOI: 10.1053/j.seminhematol.2024.07.004.
- Mina A, Greenberg P, Deeg H. How I reduce and treat posttransplant relapse of MDS. Blood 2024, 143: 1344-1354. PMID: 38306658, PMCID: PMC11443576, DOI: 10.1182/blood.2023023005.
- Mina A, Pavletic S, Aplan P. The evolution of preclinical models for myelodysplastic neoplasms. Leukemia 2024, 38: 683-691. PMID: 38396286, PMCID: PMC10997513, DOI: 10.1038/s41375-024-02181-2.
- Zhao A, Pirsl F, Steinberg S, Holtzman N, Schulz E, Mina A, Mays J, Cowen E, Comis L, Joe G, Yanovski J, Pavletic S. Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease. Bone Marrow Transplantation 2023, 58: 1377-1383. PMID: 37684526, PMCID: PMC11897997, DOI: 10.1038/s41409-023-02097-y.
- Iland H, Russell N, Dillon R, Schuh A, Tedjaseputra A, Wei A, Khwaja A, Knapper S, Lane S, Reynolds J, McMullin M, Martin A, Tan P, Taussig D, Wong A, Taper J, Fraga C, Kelly R, Tawana K, Mehta P, Mina A, Altman J, Mølle I, Tauro S, Tholouli E. Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation. Blood Advances 2023, 7: 2580-2585. PMID: 36075018, PMCID: PMC10250923, DOI: 10.1182/bloodadvances.2022007126.
- Batalini F, Mina L, Mina A. Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Letter. Clinical Cancer Research 2023, 29: 1157. PMID: 36916193, DOI: 10.1158/1078-0432.ccr-22-3510.
- Mina A, Curtis L, West K, Yau Y, Cowen E, Hakim F, Pavletic S. Collection of peripheral blood mononucleated cells for chronic graft-versus-host disease immunology research: safety and effectiveness of leukapheresis in 132 patients. Journal Of Translational Medicine 2022, 20: 519. PMID: 36348353, PMCID: PMC9644487, DOI: 10.1186/s12967-022-03708-w.
- Mina A, Galvez C, Karmali R, Mulcahy M, Mi X, Kocherginsky M, Gurley M, Katam N, Gradishar W, Altman J, Ison M, Tsarwhas D, George C, Winter J, Gordon L, Wehbe F, Platanias L. Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area. Cancers 2022, 14: 2209. PMID: 35565336, PMCID: PMC9105648, DOI: 10.3390/cancers14092209.
- Mina A, Pro B. T time: Emerging and new therapies for peripheral T-cell lymphoma. Blood Reviews 2021, 52: 100889. PMID: 34716031, DOI: 10.1016/j.blre.2021.100889.
- Suarez M, Blyth G, Mina A, Kosciuczuk E, Dolniak B, Dinner S, Altman J, Eklund E, Saleiro D, Beauchamp E, Platanias L. Inhibitory effects of Tomivosertib in acute myeloid leukemia. Oncotarget 2021, 12: 955-966. PMID: 34012509, PMCID: PMC8121614, DOI: 10.18632/oncotarget.27952.
- Mina A, Small S, Platanias L. Convalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections. Leukemia & Lymphoma 2021, 62: 1284-1286. PMID: 33729089, DOI: 10.1080/10428194.2021.1897808.
- Mina A, Platanias L. Increasing megakaryopoiesis without promoting the malignant clone in myeloid malignancies. Leukemia & Lymphoma 2020, 61: 2289-2291. PMID: 32779514, DOI: 10.1080/10428194.2020.1802453.
- Mina A, van Besien K, Platanias L. Hematological manifestations of COVID-19. Leukemia & Lymphoma 2020, 61: 2790-2798. PMID: 32643489, DOI: 10.1080/10428194.2020.1788017.
- Gao J, Chen Y, Mina A, Altman J, Kim K, Zhang Y, Lu X, Jennings L, Sukhanova M. Unique morphologic and genetic characteristics of acute myeloid leukemia with chromothripsis: a clinicopathologic study from a single institution. Human Pathology 2020, 98: 22-31. PMID: 32088209, DOI: 10.1016/j.humpath.2020.02.003.
- Mina A, Aljitawi O. Use of hyperbaric oxygen in hematopoietic cell transplantation to aid post-transplant recovery. Journal Of Comparative Effectiveness Research 2020, 9: 149-153. PMID: 31992055, DOI: 10.2217/cer-2019-0193.
- Kosciuczuk E, Kar A, Blyth G, Fischietti M, Abedin S, Mina A, Siliezar R, Rzymski T, Brzozka K, Eklund E, Beauchamp E, Eckerdt F, Saleiro D, Platanias L. Inhibitory effects of SEL201 in acute myeloid leukemia. Oncotarget 2019, 10: 7112-7121. PMID: 31903169, PMCID: PMC6935253, DOI: 10.18632/oncotarget.27388.
- Rahimi N, Zhang Y, Mina A, Altman J, Sukhanova M, Frankfurt O, Jennings L, Lu X, Behdad A, Chen Q, Chen Y, Gao J. An integrative approach reveals genetic complexity and epigenetic perturbation in acute promyelocytic leukemia: a single institution experience. Human Pathology 2019, 91: 1-10. PMID: 31125631, DOI: 10.1016/j.humpath.2019.05.008.
- Heuser M, Mina A, Stein E, Altman J. How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy. American Society Of Clinical Oncology Educational Book 2019, 39: 411-420. PMID: 31099617, DOI: 10.1200/edbk_238687.
- Mina A, Stein B. Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients? Current Hematologic Malignancy Reports 2019, 14: 137-144. PMID: 31041670, DOI: 10.1007/s11899-019-00514-y.
- Mina A, Vakkalagadda C, Pro B. Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy. Cancers 2019, 11: 421. PMID: 30934568, PMCID: PMC6468730, DOI: 10.3390/cancers11030421.
- Mina A, Shune L, Abdelhakim H, Lin T, Ganguly S, Baran A, Singh A, Abhyankar S, McGuirk J, Allin D, Aljitawi O. Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment. Annals Of Hematology 2018, 98: 481-489. PMID: 30382305, DOI: 10.1007/s00277-018-3532-1.
- Kharfan‐Dabaja M, Sheets K, Kumar A, Murthy H, Nishihori T, Tsalatsanis A, Mina A, Mathews J, Ayala E, Chavez J, Perez L, Betts B, Anasetti C, Pidala J. Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft‐versus‐host disease score. British Journal Of Haematology 2018, 180: 854-862. PMID: 29345306, DOI: 10.1111/bjh.15105.
- Mina A, Sus J, Sleiman E, Pinilla-Ibarz J, Awan F, Kharfan-Dabaja M. Using prognostic models in CLL to personalize approach to clinical care: Are we there yet? Blood Reviews 2017, 32: 159-166. PMID: 29122300, DOI: 10.1016/j.blre.2017.10.003.
- Murthy H, Sheets K, Kumar A, Nishihori T, Mina A, Chavez J, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts B, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona J, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja M. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Transplantation And Cellular Therapy 2017, 24: 400-405. PMID: 29032266, DOI: 10.1016/j.bbmt.2017.09.022.
- Tfayli A, Rafei H, Mina A, Khalil M, Fakhreddin N, Mahfouz R, Hamouri S, Farhat F, Salem Z, Dbouk H, Rabee H, Saghir N, Shamseddine A, Makarem J, Bitar N, Mougharbil A, Assi H, Temraz S, Mukherji D, Matalka I, Zaatari G. Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis. Asian Pacific Journal Of Cancer Prevention 2017, 18: 107-114. PMID: 28240017, PMCID: PMC5563085, DOI: 10.22034/apjcp.2017.18.1.107.
- Rafei H, Khalil M, Hassoun Y, Mina A, Nasser Z, Tfayli A. Perspective of Lebanese oncologists on the symptom burden among adult cancer patients. Lebanese Medical Journal 2016, 64: 200-4. PMID: 29845844, DOI: 10.12816/0033790.
- Hiler S, Mina A, Mina L. Breast Cancer Risk Factors. 2016, 5-11. DOI: 10.1007/978-3-319-19437-0_2.
- Mina A, Mina L. BRCA Patient Population. 2016, 49-57. DOI: 10.1007/978-3-319-19437-0_5.
- Mina A, Mina L. Introduction. 2016, 1-4. DOI: 10.1007/978-3-319-19437-0_1.
- Hassoun Y, J Khoury N, Rafei H, Mina A, Tfayli A. Chemotherapy induced inflammation due to cosmetic oils: a case report. Case Reports In Internal Medicine 2015, 2 DOI: 10.5430/crim.v2n3p49.
- Mina A, Rafei H, Khalil M, Hassoun Y, Nasser Z, Tfayli A. Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients. BMC Cancer 2015, 15: 10. PMID: 25605569, PMCID: PMC4311428, DOI: 10.1186/s12885-014-1004-0.
- Rafei H, Jabak S, Mina A, Tfayli A. Pleurodesis in malignant pleural effusions: Outcome and predictors of success. Integrative Cancer Science And Therapeutics 2015, 2 DOI: 10.15761/icst.1000144.
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Biography
Alain Mina, MD, specializes in medical oncology and hematology, with a focus on leukemia as well as stem cell transplants and cell therapy. Dr. Mina is dedicated to diagnosing and treating blood-related cancers, offering patients a combination of chemotherapy and advanced cellular therapies to manage their conditions effectively.
As an assistant professor of medicine at Yale School of Medicine, Dr. Mina conducts research of myeloid malignancies, such as myelodysplastic syndromes and acute myeloid leukemia. He focuses on discovering new therapies that can be tested in clinical trials.
Dr. Mina received his medical degree from the American University of Beirut in Lebanon, followed by a residency at University of Kansas Medical Center. He completed fellowships in hematology and oncology at McGaw Medical Center of Northwestern University, and in blood and marrow transplantation and cellular therapy at Stanford University Medical Center.
Titles
- Assistant Professor of Medicine (Medical Oncology & Hematology)
Education & Training
- MDAmerican University of Beirut
Languages Spoken
- العربية (Arabic)
- English
- Français (French)
Additional Information
- Mina A, Xu Y, Kapustyan T, Dhalla M, Chen C, Kamalakar R, Lin C, Ma E, Montez M, Wu Z, Yee T, Sun H, Rava A, Kim S, Huntington S, Zeidan A. Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy. Leukemia & Lymphoma 2026, ahead-of-print: 1-9. PMID: 42437458, DOI: 10.1080/10428194.2026.2691911.
- Alhajahjeh A, Beke K, Grimshaw A, Aguirre L, Mina A, Podoltsev N, Mendez L, Stahl M, Zeidan A, Bewersdorf J. Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis. Leukemia & Lymphoma 2026, 67: 1662-1674. PMID: 42251692, DOI: 10.1080/10428194.2026.2682397.
- Zhao A, Pirsl F, Parkin J, Mina A, Hishmeh R, Holtzman N, Schulz E, Pavletic S, Jurdi N. Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-versus-Host Disease. Transplantation And Cellular Therapy 2026, s2666-6367(26)00427-6. PMID: 42208939, PMCID: PMC13403212, DOI: 10.1016/j.jtct.2026.05.034.
- Mina A, Calvo K, McKinnon K, Raman A, Wang W, Cunningham L, Liu Y, Alexander R, Larson D, Pavletic S, McGraw K. Targeting the IL-8 axis in high-risk myelodysplastic syndromes: a clinical experience with antibody blockade combined with decitabine/cedazuridine. Leukemia & Lymphoma 2026, 67: 1740-1748. PMID: 42047494, DOI: 10.1080/10428194.2026.2661078.
- Bewersdorf J, Wang R, Mendez L, Mina A, Aguirre L, Stahl M, Zeidan A, Ma X, Podoltsev N. Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States. Cancer 2026, 132: e70415. PMID: 42033416, DOI: 10.1002/cncr.70415.
- Bewersdorf J, Mina A, Stahl M, Zeidan A. A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions. Nature Reviews Clinical Oncology 2026, 23: 481-500. PMID: 41981151, DOI: 10.1038/s41571-026-01141-2.
- Mina A, Zeidan A. Targeting metabolism in acute myeloid leukemia: the next therapeutic frontier? Chinese Clinical Oncology 2026, 15: 24-24. PMID: 42145008, DOI: 10.21037/cco-2025-1-191.
- Mina A, Zeidan A. Pharmacologic progress in higher-risk MDS: an uphill battle. Expert Opinion On Pharmacotherapy 2026, 27: 193-210. PMID: 41804943, DOI: 10.1080/14656566.2026.2644384.
- Beauchamp E, Jain A, Clutter M, Nahotko D, Fajardo E, Vagadia P, Dunne S, Mina A, Fischietti M, Oku C, Blyth G, Mishra R, Karras E, Radecki S, Lantz C, Addepalli S, Modi M, Zou L, Cho B, Goo Y, Rossoff J, Fish E, Saleiro D, Schiltz G, Platanias L. Development of a SIN1 targeting inhibitor as a novel therapeutic approach for the treatment of malignancies. Molecular Cancer Therapeutics 2025, 25: 1111-1129. PMID: 41423418, PMCID: PMC12904549, DOI: 10.1158/1535-7163.mct-25-0298.
- Alhajahjeh A, Woite N, Rolles B, Stempel J, Mina A, Mendez L, Kewan T, Podoltsev N, Stahl M, Grimshaw A, Zeidan A, Bewersdorf J. Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis. Blood Advances 2025, 9: 6511-6523. PMID: 40966428, PMCID: PMC12767819, DOI: 10.1182/bloodadvances.2025017611.
- Mina A. Facing Death. JCO Oncology Practice 2025, 22: 732-734. PMID: 41380109, DOI: 10.1200/op-25-00864.
- Schulz E, Curtis L, Holtzman N, Steinberg S, Wloka K, Ostojic A, Mina A, El Jurdi N, Pirsl F, Carpenter A, Golagha M, Sirajuddin A, Heller T, Shaffer B, Hakim F, Rubin J, Gress R, Pavletic S. Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT. Blood 2025, 146: 944-950. PMID: 40331908, PMCID: PMC12783510, DOI: 10.1182/blood.2024028303.
- Jurdi N, Waldman M, Schulz E, Mina A, Li G, Carpenter A, Theis J, Sethi S, Caza T, Seshan S, Pavletic S. Diagnostic approaches for haematopoietic cell transplantation‐associated membranous nephropathy: Novel underutilized tools. British Journal Of Haematology 2025, 207: 1138-1142. PMID: 40589069, PMCID: PMC12302402, DOI: 10.1111/bjh.20232.
- Hoff F, Schulz E, Pavletic S, Mina A. Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance. Blood Reviews 2025, 74: 101319. PMID: 40582916, PMCID: PMC12308840, DOI: 10.1016/j.blre.2025.101319.
- Abdelhakim H, Hebishy A, Shune L, McGuirk J, Baran A, Allin D, Mina A, Aljitawi O. Impact of hyperbaric oxygen on post-UCB transplant blood transfusion and growth factor support. Transfusion And Apheresis Science 2025, 64: 104176. PMID: 40543291, DOI: 10.1016/j.transci.2025.104176.
- Mina A, Madanat Y, Abaza Y, Zeidan A. Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights. Blood Reviews 2025, 73: 101301. PMID: 40450506, DOI: 10.1016/j.blre.2025.101301.
- Jurdi N, Holtzman N, Hishmeh R, Mina A, Schulz E, Stokes A, Li G, Schmidt K, Figg W, Micheletti N, Mays J, Cowen E, Pavletic S, Pusic I. A phase 2 study of single agent ibrutinib for first‐line treatment of chronic graft‐versus‐host disease: A new paradigm and lessons learned. British Journal Of Haematology 2025, 206: 1822-1827. PMID: 40322855, PMCID: PMC12302506, DOI: 10.1111/bjh.20069.
- Mina A, Komrokji R. How I treat higher-risk MDS. Blood 2025, 145: 2002-2011. PMID: 39808802, PMCID: PMC12782972, DOI: 10.1182/blood.2024025271.
- Schulz E, Pirsl F, McGraw K, Nousome D, Liu Y, Goklemez S, Mina A, Holtzman N, El Jurdi N, Pavletic S. Prevalence of clonal hematopoiesis of indeterminate potential in patients with severe chronic graft-versus-host disease. Bone Marrow Transplantation 2025, 60: 725-728. PMID: 40057632, DOI: 10.1038/s41409-025-02537-x.
- Mina A, McGraw K, Cunningham L, Kim N, Jen E, Calvo K, Ehrlich L, Aplan P, Garcia-Manero G, Foran J, Garcia J, Zeidan A, DeZern A, Komrokji R, Sekeres M, Scott B, Buckstein R, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic S, Norsworthy K. Advancing drug development in myelodysplastic syndromes. Blood Advances 2025, 9: 1095-1104. PMID: 39786387, PMCID: PMC11914162, DOI: 10.1182/bloodadvances.2024014865.
- Mina A. Targeted therapy in acute T-cell leukemia/lymphoma: are we close? Leukemia & Lymphoma 2024, 65: 2071-2073. PMID: 39618171, DOI: 10.1080/10428194.2024.2432575.
- Mendoza T, King A, Vera E, Mina A, McGraw K, Pavletic S, Armstrong T. Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes. Seminars In Hematology 2024, 61: 457-464. PMID: 39542751, DOI: 10.1053/j.seminhematol.2024.10.010.
- Schulz E, Pavletic S, Mina A. Allogeneic hematopoietic cell transplantation in elderly patients with myelodysplastic syndromes: Considerations and challenges. Seminars In Hematology 2024, 61: 420-430. PMID: 39523201, PMCID: PMC11646184, DOI: 10.1053/j.seminhematol.2024.10.004.
- Gavrilova T, Schulz E, Mina A. Breaking Boundaries: Immunotherapy for Myeloid Malignancies. Cancers 2024, 16: 2780. PMID: 39199554, PMCID: PMC11352449, DOI: 10.3390/cancers16162780.
- Czech M, Schulz E, Mina A, Gea-Banacloche J. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes. Seminars In Hematology 2024, 61: 348-357. PMID: 39198132, PMCID: PMC11646186, DOI: 10.1053/j.seminhematol.2024.07.004.
- Mina A, Greenberg P, Deeg H. How I reduce and treat posttransplant relapse of MDS. Blood 2024, 143: 1344-1354. PMID: 38306658, PMCID: PMC11443576, DOI: 10.1182/blood.2023023005.
- Mina A, Pavletic S, Aplan P. The evolution of preclinical models for myelodysplastic neoplasms. Leukemia 2024, 38: 683-691. PMID: 38396286, PMCID: PMC10997513, DOI: 10.1038/s41375-024-02181-2.
- Zhao A, Pirsl F, Steinberg S, Holtzman N, Schulz E, Mina A, Mays J, Cowen E, Comis L, Joe G, Yanovski J, Pavletic S. Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease. Bone Marrow Transplantation 2023, 58: 1377-1383. PMID: 37684526, PMCID: PMC11897997, DOI: 10.1038/s41409-023-02097-y.
- Iland H, Russell N, Dillon R, Schuh A, Tedjaseputra A, Wei A, Khwaja A, Knapper S, Lane S, Reynolds J, McMullin M, Martin A, Tan P, Taussig D, Wong A, Taper J, Fraga C, Kelly R, Tawana K, Mehta P, Mina A, Altman J, Mølle I, Tauro S, Tholouli E. Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation. Blood Advances 2023, 7: 2580-2585. PMID: 36075018, PMCID: PMC10250923, DOI: 10.1182/bloodadvances.2022007126.
- Batalini F, Mina L, Mina A. Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Letter. Clinical Cancer Research 2023, 29: 1157. PMID: 36916193, DOI: 10.1158/1078-0432.ccr-22-3510.
- Mina A, Curtis L, West K, Yau Y, Cowen E, Hakim F, Pavletic S. Collection of peripheral blood mononucleated cells for chronic graft-versus-host disease immunology research: safety and effectiveness of leukapheresis in 132 patients. Journal Of Translational Medicine 2022, 20: 519. PMID: 36348353, PMCID: PMC9644487, DOI: 10.1186/s12967-022-03708-w.
- Mina A, Galvez C, Karmali R, Mulcahy M, Mi X, Kocherginsky M, Gurley M, Katam N, Gradishar W, Altman J, Ison M, Tsarwhas D, George C, Winter J, Gordon L, Wehbe F, Platanias L. Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area. Cancers 2022, 14: 2209. PMID: 35565336, PMCID: PMC9105648, DOI: 10.3390/cancers14092209.
- Mina A, Pro B. T time: Emerging and new therapies for peripheral T-cell lymphoma. Blood Reviews 2021, 52: 100889. PMID: 34716031, DOI: 10.1016/j.blre.2021.100889.
- Suarez M, Blyth G, Mina A, Kosciuczuk E, Dolniak B, Dinner S, Altman J, Eklund E, Saleiro D, Beauchamp E, Platanias L. Inhibitory effects of Tomivosertib in acute myeloid leukemia. Oncotarget 2021, 12: 955-966. PMID: 34012509, PMCID: PMC8121614, DOI: 10.18632/oncotarget.27952.
- Mina A, Small S, Platanias L. Convalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections. Leukemia & Lymphoma 2021, 62: 1284-1286. PMID: 33729089, DOI: 10.1080/10428194.2021.1897808.
- Mina A, Platanias L. Increasing megakaryopoiesis without promoting the malignant clone in myeloid malignancies. Leukemia & Lymphoma 2020, 61: 2289-2291. PMID: 32779514, DOI: 10.1080/10428194.2020.1802453.
- Mina A, van Besien K, Platanias L. Hematological manifestations of COVID-19. Leukemia & Lymphoma 2020, 61: 2790-2798. PMID: 32643489, DOI: 10.1080/10428194.2020.1788017.
- Gao J, Chen Y, Mina A, Altman J, Kim K, Zhang Y, Lu X, Jennings L, Sukhanova M. Unique morphologic and genetic characteristics of acute myeloid leukemia with chromothripsis: a clinicopathologic study from a single institution. Human Pathology 2020, 98: 22-31. PMID: 32088209, DOI: 10.1016/j.humpath.2020.02.003.
- Mina A, Aljitawi O. Use of hyperbaric oxygen in hematopoietic cell transplantation to aid post-transplant recovery. Journal Of Comparative Effectiveness Research 2020, 9: 149-153. PMID: 31992055, DOI: 10.2217/cer-2019-0193.
- Kosciuczuk E, Kar A, Blyth G, Fischietti M, Abedin S, Mina A, Siliezar R, Rzymski T, Brzozka K, Eklund E, Beauchamp E, Eckerdt F, Saleiro D, Platanias L. Inhibitory effects of SEL201 in acute myeloid leukemia. Oncotarget 2019, 10: 7112-7121. PMID: 31903169, PMCID: PMC6935253, DOI: 10.18632/oncotarget.27388.
- Rahimi N, Zhang Y, Mina A, Altman J, Sukhanova M, Frankfurt O, Jennings L, Lu X, Behdad A, Chen Q, Chen Y, Gao J. An integrative approach reveals genetic complexity and epigenetic perturbation in acute promyelocytic leukemia: a single institution experience. Human Pathology 2019, 91: 1-10. PMID: 31125631, DOI: 10.1016/j.humpath.2019.05.008.
- Heuser M, Mina A, Stein E, Altman J. How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy. American Society Of Clinical Oncology Educational Book 2019, 39: 411-420. PMID: 31099617, DOI: 10.1200/edbk_238687.
- Mina A, Stein B. Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients? Current Hematologic Malignancy Reports 2019, 14: 137-144. PMID: 31041670, DOI: 10.1007/s11899-019-00514-y.
- Mina A, Vakkalagadda C, Pro B. Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy. Cancers 2019, 11: 421. PMID: 30934568, PMCID: PMC6468730, DOI: 10.3390/cancers11030421.
- Mina A, Shune L, Abdelhakim H, Lin T, Ganguly S, Baran A, Singh A, Abhyankar S, McGuirk J, Allin D, Aljitawi O. Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment. Annals Of Hematology 2018, 98: 481-489. PMID: 30382305, DOI: 10.1007/s00277-018-3532-1.
- Kharfan‐Dabaja M, Sheets K, Kumar A, Murthy H, Nishihori T, Tsalatsanis A, Mina A, Mathews J, Ayala E, Chavez J, Perez L, Betts B, Anasetti C, Pidala J. Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft‐versus‐host disease score. British Journal Of Haematology 2018, 180: 854-862. PMID: 29345306, DOI: 10.1111/bjh.15105.
- Mina A, Sus J, Sleiman E, Pinilla-Ibarz J, Awan F, Kharfan-Dabaja M. Using prognostic models in CLL to personalize approach to clinical care: Are we there yet? Blood Reviews 2017, 32: 159-166. PMID: 29122300, DOI: 10.1016/j.blre.2017.10.003.
- Murthy H, Sheets K, Kumar A, Nishihori T, Mina A, Chavez J, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts B, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona J, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja M. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Transplantation And Cellular Therapy 2017, 24: 400-405. PMID: 29032266, DOI: 10.1016/j.bbmt.2017.09.022.
- Tfayli A, Rafei H, Mina A, Khalil M, Fakhreddin N, Mahfouz R, Hamouri S, Farhat F, Salem Z, Dbouk H, Rabee H, Saghir N, Shamseddine A, Makarem J, Bitar N, Mougharbil A, Assi H, Temraz S, Mukherji D, Matalka I, Zaatari G. Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis. Asian Pacific Journal Of Cancer Prevention 2017, 18: 107-114. PMID: 28240017, PMCID: PMC5563085, DOI: 10.22034/apjcp.2017.18.1.107.
- Rafei H, Khalil M, Hassoun Y, Mina A, Nasser Z, Tfayli A. Perspective of Lebanese oncologists on the symptom burden among adult cancer patients. Lebanese Medical Journal 2016, 64: 200-4. PMID: 29845844, DOI: 10.12816/0033790.
- Hiler S, Mina A, Mina L. Breast Cancer Risk Factors. 2016, 5-11. DOI: 10.1007/978-3-319-19437-0_2.
- Mina A, Mina L. BRCA Patient Population. 2016, 49-57. DOI: 10.1007/978-3-319-19437-0_5.
- Mina A, Mina L. Introduction. 2016, 1-4. DOI: 10.1007/978-3-319-19437-0_1.
- Hassoun Y, J Khoury N, Rafei H, Mina A, Tfayli A. Chemotherapy induced inflammation due to cosmetic oils: a case report. Case Reports In Internal Medicine 2015, 2 DOI: 10.5430/crim.v2n3p49.
- Mina A, Rafei H, Khalil M, Hassoun Y, Nasser Z, Tfayli A. Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients. BMC Cancer 2015, 15: 10. PMID: 25605569, PMCID: PMC4311428, DOI: 10.1186/s12885-014-1004-0.
- Rafei H, Jabak S, Mina A, Tfayli A. Pleurodesis in malignant pleural effusions: Outcome and predictors of success. Integrative Cancer Science And Therapeutics 2015, 2 DOI: 10.15761/icst.1000144.
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511